PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32828804-0	2020	Proof that the high molecular weight immunophilin FKBP52 mediates the in vivo neuroregenerative effect of the macrolide FK506.	Tacrolimus	120-125	FK506 binding protein 4	Mus musculus	37-56	
32828804-6	2020	The experimental evidence demonstrates that the neurotrophic actions of FK506 are the consequence of its binding to FKBP52, whereas FK506 interaction with the close-related partner immunophilin FKBP51 antagonises the function of FKBP52.	Tacrolimus	72-77	FK506 binding protein 4	Mus musculus	116-122	
32828804-6	2020	The experimental evidence demonstrates that the neurotrophic actions of FK506 are the consequence of its binding to FKBP52, whereas FK506 interaction with the close-related partner immunophilin FKBP51 antagonises the function of FKBP52.	Tacrolimus	132-137	FK506 binding protein 4	Mus musculus	229-235	
25986565-7	2015	Finally, the fact that FKBP52 is already a validated target of the clinically approved immunosuppressive drug, FK506 (Tacrolimus), indicates that FKBP52 is a "druggable" protein.	Tacrolimus	111-116	FK506 binding protein 4	Mus musculus	23-29	
28689771-0	2018	Immunosuppression with tacrolimus improved implantation and rescued expression of uterine progesterone receptor and its co-regulators FKBP52 and PIASy at nidation in the obese and diabetic mice: Comparative studies with metformin.	Tacrolimus	23-33	FK506 binding protein 4	Mus musculus	134-140	
28689771-8	2018	Therapeutic interventions with tacrolimus or metformin normalized the expression of decidual IFNgamma, PGR and FKBP52, increased co-localization of protein inhibitor of activated STATy (PIASy) to PGR and resulted in the upregulation of uterine IL11and LIF.	Tacrolimus	31-41	FK506 binding protein 4	Mus musculus	111-117	
25986565-7	2015	Finally, the fact that FKBP52 is already a validated target of the clinically approved immunosuppressive drug, FK506 (Tacrolimus), indicates that FKBP52 is a "druggable" protein.	Tacrolimus	118-128	FK506 binding protein 4	Mus musculus	23-29	
25986565-7	2015	Finally, the fact that FKBP52 is already a validated target of the clinically approved immunosuppressive drug, FK506 (Tacrolimus), indicates that FKBP52 is a "druggable" protein.	Tacrolimus	118-128	FK506 binding protein 4	Mus musculus	146-152	
25986565-7	2015	Finally, the fact that FKBP52 is already a validated target of the clinically approved immunosuppressive drug, FK506 (Tacrolimus), indicates that FKBP52 is a "druggable" protein.	Tacrolimus	111-116	FK506 binding protein 4	Mus musculus	146-152	
22091865-1	2012	BACKGROUND AND PURPOSE The immunosuppressive macrolide FK506 (tacrolimus) shows neuroregenerative action by a mechanism that appears to involve the Hsp90-binding immunophilin FKBP52.	Tacrolimus	55-60	FK506 binding protein 4	Mus musculus	175-181	
25505617-7	2014	Using 52KO and 51KO MEF cells, FK506 potentiated GR activity in 51KO cells but could not do so in 52KO cells, suggesting FKBP52 as the major target of FK506 action.	Tacrolimus	31-36	FK506 binding protein 4	Mus musculus	121-127	
25505617-7	2014	Using 52KO and 51KO MEF cells, FK506 potentiated GR activity in 51KO cells but could not do so in 52KO cells, suggesting FKBP52 as the major target of FK506 action.	Tacrolimus	151-156	FK506 binding protein 4	Mus musculus	121-127	
22091865-1	2012	BACKGROUND AND PURPOSE The immunosuppressive macrolide FK506 (tacrolimus) shows neuroregenerative action by a mechanism that appears to involve the Hsp90-binding immunophilin FKBP52.	Tacrolimus	62-72	FK506 binding protein 4	Mus musculus	175-181	
22091865-6	2012	KEY RESULTS In undifferentiated cells, FKBP52, Hsp90 and p23 are located in the cell nucleus, forming an annular structure that disassembles when the differentiation process is triggered by FK506.	Tacrolimus	190-195	FK506 binding protein 4	Mus musculus	39-45	
17307907-1	2007	FKBP52 is a member of the FK506-binding family of immunophilins and serves as a co-chaperone for steroid hormone nuclear receptors to govern appropriate hormone action in target tissues.	Tacrolimus	26-31	FK506 binding protein 4	Mus musculus	0-6	
34072036-4	2021	Glucocorticoid signaling is mediated via glucocorticoid receptors, 11beta-hydroxysteroid dehydrogenases, and the FK506-binding immunophilins, Fkbp4 and Fkbp5.	Tacrolimus	113-118	FK506 binding protein 4	Mus musculus	142-147